Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

PURPOSE: To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). PATIEN...

Full description

Saved in:
Bibliographic Details
Main Authors: Garcia-Manero, Guillermo, Gore, Steven D., Cogle, Christopher, Ward, Renee, Shi, Tao, MacBeth, Kyle J., Laille, Eric, Giordano, Heidi, Sakoian, Sarah, Jabbour, Elias, Kantarjian, Hagop, Skikne, Barry
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2011
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675699/
https://ncbi.nlm.nih.gov/pubmed/21576646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.4226
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items